– NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform – Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected in Q1 2023 – Phase 1 trial with...
Former Pfizer Internal Medicine CSO joins the Boardas an independent board member Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a biotech company developing novel and innovative strategies for the treatment of...
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated liver disease (IFALD) SEFA-6179 is NST’s third programme to enter...
Financing co-led by Ysios Capital and Forbion Growth Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and...
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severityResults presented at the AASLD Liver Meeting Digital Experience™ 2021 Significant decreases in key markers of...
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent,...